Accelerating Advancement In Gene Therapy By Improving Downstream Purification Of Viral Vectors
Source: Thermo Fisher Scientific
By Orjana Terova, John Li, Jessica de Rooij, Pim Hermans, Alejandro Becerra and Frank Detmers; Thermo Fisher Scientific
Over the past decade, gene therapy applications and their importance in the biopharmaceutical industry have been increasing. The non-pathogenic adeno-associated virus (AAV) has emerged as the vector of choice for many therapies but purification of biologically active viral vectors for large-scale commercial use is a challenge. Thermo Fisher Scientific has developed downstream purification solutions, enabling the scale-up of viral vector production.
VIRAL VECTOR PURIFICATION CHALLENGES
- Multiple chromatography steps & concentration needed due to challenging feedstock
- Long process development lead times
- Cumulative yield losses with each unit operation
VIEW THE POSTER!
Log In
Signing up provides unlimited access to:
Free Sign Up

Signing up provides unlimited access to:
- Trend and Leadership Articles
- Case Studies
- Extensive Product Database
- Premium Content
HELLO. PLEASE LOG IN.
X
Not yet a member of Pharmaceutical Online? Register today.
ACCOUNT SIGN UP
X
Please fill in your account details
ACCOUNT SIGN UP
Thermo Fisher Scientific
This website uses cookies to ensure you get the best experience on our website. Learn more